XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
6.72
+0.23 (3.61%)
Nov 21, 2024, 11:54 AM EST - Market open
XBiotech Employees
XBiotech had 82 employees as of December 31, 2023. The number of employees decreased by 3 or -3.53% compared to the previous year.
Employees
82
Change (1Y)
-3
Growth (1Y)
-3.53%
Revenue / Employee
n/a
Profits / Employee
-$398,268
Market Cap
204.85M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
MacroGenics | 339 |
Amarin Corporation | 275 |
Editas Medicine | 265 |
Personalis | 225 |
Quantum-Si incorporated | 159 |
Solid Biosciences | 88 |
Acrivon Therapeutics | 61 |
Lexeo Therapeutics | 58 |
XBIT News
- 5 months ago - What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - Benzinga
- 5 months ago - XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - GlobeNewsWire
- 6 months ago - XBiotech: Several Shots On Goal In Big Target Market Indications - Seeking Alpha
- 11 months ago - XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus - GlobeNewsWire
- 1 year ago - Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer - GlobeNewsWire
- 1 year ago - XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - GlobeNewsWire